Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health conditions. Clinical trials show that people can lose up to 20 percent ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to treat… ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

Global health insurance company The Cigna Group CI is set to report second-quarter 2025 results on July 31, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported ...

CI's Q2 results are likely to hinge on Evernorth's growth as core healthcare revenues and premiums face steep declines.

Today’s Forbes Daily covers Pacific tsunami activity after powerful quake, Trump breaks with Netanyahu over Gaza, the Forbes 50 Over 50, a railroad merger and more.

Novo Nordisk shares dropped as much as 17% Tuesday after the obesity drugmaker cut its full-year sales and profit outlook for the second time in 2025, according to Reuters. The company cited ...

Stocks closed lower Tuesday as investors took a breather from a rally that had pushed major indexes to a series of record highs in recent weeks.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Trump’s trade deal with the E.U. may lead to higher prices for brand-name drugs in the U.S., including the blockbuster medications Ozempic and Wegovy, experts say.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in ...